Dimensional Fund Advisors LP Grows Position in Amphastar Pharmaceuticals Inc (AMPH)
Dimensional Fund Advisors LP lifted its holdings in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 17.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,558,113 shares of the company’s stock after acquiring an additional 226,271 shares during the period. Dimensional Fund Advisors LP’s holdings in Amphastar Pharmaceuticals were worth $27,844,000 as of its most recent filing with the SEC.
Other hedge funds have also added to or reduced their stakes in the company. Victory Capital Management Inc. grew its stake in shares of Amphastar Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock valued at $100,000 after acquiring an additional 842 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Amphastar Pharmaceuticals in the second quarter valued at about $111,000. BNP Paribas Arbitrage SA grew its stake in shares of Amphastar Pharmaceuticals by 58.2% in the second quarter. BNP Paribas Arbitrage SA now owns 10,545 shares of the company’s stock valued at $188,000 after acquiring an additional 3,880 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its stake in shares of Amphastar Pharmaceuticals by 58.8% in the third quarter. Municipal Employees Retirement System of Michigan now owns 13,390 shares of the company’s stock valued at $239,000 after acquiring an additional 4,960 shares in the last quarter. Finally, Thrivent Financial For Lutherans grew its stake in shares of Amphastar Pharmaceuticals by 7.2% in the second quarter. Thrivent Financial For Lutherans now owns 21,610 shares of the company’s stock valued at $386,000 after acquiring an additional 1,460 shares in the last quarter. Institutional investors and hedge funds own 44.14% of the company’s stock.
AMPH has been the topic of several research reports. Needham & Company LLC upped their price target on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Friday, December 1st. Jefferies Group set a $19.00 price target on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, October 29th. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research note on Thursday, October 19th. Piper Jaffray Companies set a $19.00 price objective on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, October 22nd. Finally, BMO Capital Markets upped their price objective on shares of Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the stock a “market perform” rating in a research report on Friday, November 10th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $19.50.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Wednesday, November 8th. The company reported $0.07 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The business had revenue of $57.90 million during the quarter, compared to analysts’ expectations of $57.23 million. During the same quarter in the prior year, the business posted $0.14 earnings per share. Amphastar Pharmaceuticals’s revenue was down 9.8% compared to the same quarter last year. analysts expect that Amphastar Pharmaceuticals Inc will post -0.03 EPS for the current fiscal year.
In related news, CFO William J. Peters sold 6,226 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $19.67, for a total transaction of $122,465.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Stephen B. Shohet sold 7,866 shares of the company’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $18.87, for a total transaction of $148,431.42. Following the sale, the director now directly owns 31,982 shares of the company’s stock, valued at approximately $603,500.34. The disclosure for this sale can be found here. Insiders have sold 72,787 shares of company stock valued at $1,359,684 in the last ninety days. 11.10% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Dimensional Fund Advisors LP Grows Position in Amphastar Pharmaceuticals Inc (AMPH)” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://theolympiareport.com/2018/01/18/dimensional-fund-advisors-lp-grows-position-in-amphastar-pharmaceuticals-inc-amph.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH).
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.